SCHEDULE: BlackRock Boosts Sarepta Therapeutics Stake to 12.6%

BlackRock, Inc. has reported an increased beneficial ownership of 12.6% in Sarepta Therapeutics Inc. common stock as of December 31, 2025.

Summary

• BlackRock, Inc. has filed an Amendment No. 11 to Schedule 13G, reporting its beneficial ownership in Sarepta Therapeutics Inc. common stock.
• As of December 31, 2025, BlackRock, Inc. beneficially owns 13,232,652 shares of Sarepta Therapeutics Inc. common stock.
• This ownership represents 12.6% of the total outstanding common stock of Sarepta Therapeutics Inc.
• BlackRock, Inc. holds sole voting power over 12,913,969 shares and sole dispositive power over 13,232,652 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Sarepta Therapeutics Inc.
• iShares Core S&P Small-Cap ETF, a BlackRock entity, is noted to have an interest of more than five percent in Sarepta Therapeutics Inc. common stock.

Sentiment

Score: 7

Explanation: The filing indicates a significant and increased institutional stake by BlackRock, which is generally viewed as a positive signal of confidence in the company's value and prospects, even though it's a passive investment.

Positives

• Increased institutional ownership by a major asset manager like BlackRock can signal confidence in Sarepta Therapeutics Inc.'s long-term prospects.
• The acquisition of shares is stated to be in the ordinary course of business, indicating a standard investment strategy rather than an activist stance.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Sarepta Therapeutics Inc.'s future performance or outlook.

Management Comments

• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct." Spencer Fleming, Managing Director, BlackRock, Inc.

Industry Context

BlackRock's increased stake in Sarepta Therapeutics Inc., a biotechnology company, highlights continued institutional investor interest in the life sciences sector, particularly in companies developing innovative therapies. This aligns with broader market trends where large asset managers seek growth opportunities in specialized healthcare segments.

Stakeholder Impact

• Shareholders may perceive increased institutional confidence in Sarepta Therapeutics Inc. due to BlackRock's significant stake, potentially influencing market sentiment positively.
• The filing confirms BlackRock's passive investment intent, assuring other stakeholders that the ownership is not for control purposes.

Key Dates

Recommendation

The filing indicates a substantial and increased institutional ownership by BlackRock, a major asset manager, which can be interpreted as a vote of confidence in Sarepta Therapeutics Inc. While this alone does not provide enough fundamental information for a 'buy' or 'sell' recommendation, the increased institutional backing suggests a 'hold' for existing investors and a positive signal for those considering the stock, pending further fundamental analysis.

Keywords

Sarepta Therapeutics, BlackRock, Institutional Ownership, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals